Symeonidis Dimitrios, Paraskeva Ismini, Samara Athina A, Kissa Labrini, Valaroutsos Alexandros, Petsa Eleana, Tepetes Konstantinos
Department of Surgery, University Hospital of Larissa, Mezourlo, Larissa, Greece.
Surg J (N Y). 2024 Mar 14;10(1):e20-e24. doi: 10.1055/s-0044-1782655. eCollection 2024 Jan.
Central pancreatectomy (CP) represents an organ-preserving type of pancreatic resection. The procedure has been associated with improved long-term functional results, but increased postoperative morbidity rates, compared with the more radical resection types. The purpose of the present study was to present the outcomes of three consecutive CPs performed in our department. Between January 2021 and January 2022, three patients (A, B, and C) were submitted to a CP in our department. Relevant patient data including data of the detailed preoperative assessment, operations notes, and recovery charts were prospectively collected and reviewed for all subjects. A scheduled follow-up, at the outpatient clinic, was conducted to assess the long-term functional results. The postoperative course of patient A, a 56-year-old male, was complicated by a grade C postoperative pancreatic fistula that required a reoperation. Patient B, a 66-year-old female, developed a biochemical leak that resolved spontaneously while patient C, a 64-year-old male, had a completely uneventful recovery. The length of hospital stay for the three patients was 24, 12, and 8 days, respectively. Regarding the long-term results, patient B was lost to follow-up while both patient A and C were followed up, as outpatients, 21 and 10 months after the operation. During follow-up, in patient A, we did not record the presence of symptoms consistent with pancreatic exocrine insufficiency, the hemoglobin A1C (HbA1C) levels were 7.1% while no additional medications were needed to be prescribed to maintain the glycemic control following surgery. In patient C, a significant weight loss was recorded (body mass index reduction of 11 kg/m ) without however the presence of malabsorption-specific symptoms. The HbA1C levels were 7.7% and optimal glycemic control was achieved with oral antiglycemic agents alone. CP should be regarded as a type of pancreatic resection with certain and very limited oncological indications. An approach of balancing the advantages out of the superior postoperative functional results with the drawbacks of the increased procedure-associated morbidity could highlight the patient group that could potentially experience benefits out of this limited type of resection.
胰体尾切除术(CP)是一种保留器官的胰腺切除术。与更激进的切除类型相比,该手术与改善长期功能结果相关,但术后发病率增加。本研究的目的是展示在我们科室连续进行的三例胰体尾切除术的结果。
在2021年1月至2022年1月期间,我们科室有三名患者(A、B和C)接受了胰体尾切除术。前瞻性收集并审查了所有受试者的相关患者数据,包括详细的术前评估数据、手术记录和恢复图表。在门诊进行了定期随访,以评估长期功能结果。
患者A为56岁男性,术后病程因C级胰瘘而复杂化,需要再次手术。患者B为66岁女性,出现生化渗漏,渗漏自行缓解,而患者C为64岁男性,恢复完全顺利。三名患者的住院时间分别为24天、12天和8天。关于长期结果,患者B失访,而患者A和C在术后21个月和10个月作为门诊患者进行了随访。随访期间,在患者A中,我们未记录到与胰腺外分泌功能不全一致的症状,糖化血红蛋白(HbA1C)水平为7.1%,术后无需额外开药来维持血糖控制。在患者C中,记录到体重显著减轻(体重指数降低11kg/m²),但没有吸收不良的特异性症状。HbA1C水平为7.7%,仅通过口服降糖药就实现了最佳血糖控制。
胰体尾切除术应被视为一种具有特定且非常有限的肿瘤学适应证的胰腺切除术。一种平衡术后功能结果优势与手术相关发病率增加的缺点的方法,可能会突出可能从这种有限类型的切除术中获益的患者群体。